Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 551-557

  Marioni, Gino ^a   Giacomelli, Luciano ^a   D'Alessandro, Emiliano ^a   Staffieri, Claudia ^a   Guzzardo, Vincenza ^a   Staffieri, Alberto ^a   Blandamura, Stella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

CD105; Laryngeal carcinoma; Prognosis; Recurrence; Vascular endothelial growth factor receptor 2 (VEGFR2)

Indexed keywords

ENDOGLIN; PROTEIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AGED; ANTIGENS, CD; DISEASE-FREE SURVIVAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 40549110569     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D and Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17: 197-203, 2004.
2. Cheng J, Slavin RE, Gallagher JA, Zhu G, Biehl TR, Swanstrom LL and Hansen PD: Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases. J Hepatobiliary Pancreat Surg 11: 164-170, 2004.
3. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Taranger-Charpin C: Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905). Br J Cancer 90: 1216-1221, 2004
4. Lazaris AC, Tseleni-Balafouta S, Papathomas T, Brousalis T, Thomopoulou G, Agrogiannis G and Patsouris ES: Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur J Endocrinol 154: 827-833, 2006.
5. Fonsatti E, Altomonte M, Nicotra MR, Natali PG and Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22: 6557-6563, 2003.
6. Fonsatti E and Maio M: Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2: 18, 2004.
7. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP and Gill PS: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175: 1245-1252, 2006.
8. Lalla RV, Boisoneau DS, Spiro JD and Kreutzer DL: Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 129: 882-888, 2003.
9. Vieira JM, Santos SCR, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S and Leite V: Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153: 701-709, 2005.
10. Osada S, Imai H, Tomita H, Tokoyma Y, Okomura N, Sakashita F, Nonoka K and Sugiyama Y: Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J Gastroenterol Hepatol 21: 988-993, 2006.
11. Pillai G, Cook N, Turley H, Leek RD, Blasquez C, Pezzella F, Harris AL and Gatter KC: The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study. Histopathology 46: 209-216, 2005.
12. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C and Burian M: Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111: 1834-1841, 2001.
13. Schoefnner DJ, Matheny SL, Akahane T, Factor V, Berry A, Merlino G and Thorgeirsson UP: VEGF contributes to mammary tumor growth in trangenic mice through paracrine and autocrine mechanisms. Lab Invest 85: 608-623, 2005.
14. Kyzas PA, Stefanou D, Batistatou A and Agnantis NJ: Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 18: 485-494, 2005.
15. International Union Against Cancer: TNM Classification of Malignant Tumours. 5th ed. Wiley-Liss, New York, USA, pp. 33-37, 1997.
16. Inouè S and Spring KR: Video microscopy. The fundamentals. 2nd ed. Plenum Press, New York, USA, 1986.
17. Shannon CE: Communication in the presence of noise. Proc. Instit Radio Engineers 37: 10-21, 1949.
18. Sharma S, Sharma MC and Sarkar C: Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46: 481-489, 2005.
19. Schimming R and Marmè D: Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 24: 151-156, 2002.
20. Schimming R, Reusch P, Kuschnierz J and Schmelzeisen R: Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Cranio-Maxillofac Surg 32: 176-181, 2004.
21. Nagatsuka H, Hibi K, Gunduz M, Tsujigiwa H, Tamamura R, Sugahara T, Sasaki A and Nagai N: Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. J Oral Pathol Med 34: 70-76, 2005.
22. Marioni G, Marino F, Giacomelli L, Staffieri C, Mariuzzi ML, Violino E and de Filippis C: Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol (Stockh) 126: 633-639, 2006.
23. Chien CY, Su CY, Hwang CF, Chuang HC, Hsiao YC, Wu SL and Huang CC: Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck 28: 441-446, 2006.
24. Kyzas PA, Agnantis NJ and Stefanou D: Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 448: 768-775, 2006.
25. Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, Pruneti G, Bellone G and Cortesina C: Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 41: 147-155, 2005.
26. Marioni G, Ottaviano G, Giacomelli L, Staffieri C, Casarotti-Todeschini S, Bonandini E, Staffieri A and Blandamura S: CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol 32: 1149-1153, 2006.
27. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
28. Giatromanolaki A, Koukourakis MI, Sivridis E, Thorpe PE, Brekken RA, Konstantinos S, Fountzilas G, Gatter KC and Harris AL: Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clin Exp Metast 18: 313-319, 2000.